- Home
- AUUD vs DRMA Comparison
AUUD vs DRMA Comparison
Compare AUUD & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- DRMA
- Stock Information
- Founded
- AUUD 2012
- DRMA 2014
- Country
- AUUD United States
- DRMA United States
- Employees
- AUUD N/A
- DRMA N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- DRMA Health Care
- Exchange
- AUUD Nasdaq
- DRMA Nasdaq
- Market Cap
- AUUD 4.2M
- DRMA 3.6M
- IPO Year
- AUUD 2021
- DRMA 2021
- Fundamental
- Price
- AUUD $2.05
- DRMA $5.57
- Analyst Decision
- AUUD
- DRMA Strong Buy
- Analyst Count
- AUUD 0
- DRMA 1
- Target Price
- AUUD N/A
- DRMA $10.00
- AVG Volume (30 Days)
- AUUD 2.9M
- DRMA 37.9K
- Earning Date
- AUUD 11-06-2025
- DRMA 11-12-2025
- Dividend Yield
- AUUD N/A
- DRMA N/A
- EPS Growth
- AUUD N/A
- DRMA N/A
- EPS
- AUUD N/A
- DRMA N/A
- Revenue
- AUUD N/A
- DRMA N/A
- Revenue This Year
- AUUD N/A
- DRMA N/A
- Revenue Next Year
- AUUD N/A
- DRMA N/A
- P/E Ratio
- AUUD N/A
- DRMA N/A
- Revenue Growth
- AUUD N/A
- DRMA N/A
- 52 Week Low
- AUUD $1.85
- DRMA $5.04
- 52 Week High
- AUUD $14.60
- DRMA $23.80
- Technical
- Relative Strength Index (RSI)
- AUUD 38.35
- DRMA 47.23
- Support Level
- AUUD $2.00
- DRMA $5.41
- Resistance Level
- AUUD $2.11
- DRMA $6.23
- Average True Range (ATR)
- AUUD 0.13
- DRMA 0.39
- MACD
- AUUD 0.06
- DRMA 0.06
- Stochastic Oscillator
- AUUD 40.00
- DRMA 44.68
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.